Vacunas basadas en neoantígenos y control del cáncer: perspectivas

  • Raúl Hernando Murillo Moreno
Palabras clave: Neoplasias, Antígenos de neoplasias, Vacunas, Control cáncer

Resumen

La supervivencia global y la calidad de vida son objetivos primarios del tratamiento del cáncer. El desarrollo de terapias blanco promovió el concepto de tratamientos personalizados, los que se han evaluado principalmente mediante desenlaces centrados en el tumor y han tenido foco en tumores de baja frecuencia y estados avanzados. La inmunoterapia rompe esta tendencia y genera expectativa por su efecto en la supervivencia global y su potencial uso en una gama amplia de tumores. Dentro de esta, las vacunas basadas en neoantígenos han mostrado alta eficacia y seguridad debido a su afinidad con células T y su elevada especificidad. Basado en sus principios biológicos se revisa su posible impacto en la carga de enfermedad según la relación entre potencial inmunogénico y prevalencia por tipo de tumor, el posible efecto en la práctica clínica por su combinación con otras modalidades de tratamiento, y el efecto en el acceso al tratamiento dado su proceso de desarrollo y producción y la disponibilidad de información propia.

Descargas

La descarga de datos todavía no está disponible.

Referencias

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3

Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the Evolution of Cancer Treatment Therapies. Cancers (Basel). 2011;3(3):3279-330. https://doi.org/10.3390/cancers3033279

Murillo R, Wiesner C, Acosta J, Piñeros M, Pérez JJ, Orozco M. Modelo para el cuidado del cáncer en Colombia. Bogotá: Serie Documentos Técnicos INC No. 5; 2015.

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70. https://doi.org/10.1016/S0092-8674(00)81683-9

Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018;9:1300. https://doi.org/10.3389/fphar.2018.01300

World Health Organization. Pricing of Cancer Medicines and its Impacts. Geneva: WHO; 2018.

Albrecht B, Menu P, Tsao J, Webster K. The Next Wave of Innovation in Oncology. McKinsey Cancer Center. McKinsey&Company; 2016.

Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value Health. 2017;20(3):487-95. https://doi.org/10.1016/j.jval.2016.10.011

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, et al. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018;6(1):69. https://doi.org/10.1186/s40425-018-0377-z

Hodi FS, O'Day, SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New Eng J Med. 2010;363(8):711-23. https://doi.org/10.1056/NEJMoa1003466

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. https://doi.org/10.1056/NEJMoa1504627

Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. https://doi.org/10.1186/s13045-019-0787-5

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. https://doi.org/10.1186/s12943-019-1055-6

Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-82. https://doi.org/10.1038/nri.2017.131

Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J Immunol Res. 2018;2018:4325874. https://doi.org/10.1155/2018/4325874

Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013

Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol. 2014;10(1):41-62. https://doi.org/10.1586/1744666X.2014.865519

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459): eaat7807. https://doi.org/10.1126/scitranslmed.aat7807

Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019;37:173-200. https://doi.org/10.1146/annurev-immunol-042617-053402

Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238-46. https://doi.org/10.7150/thno.24387

Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. https://doi.org/10.1038/s41541-019-0103-y

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity Against Cancer. Nature. 2017;547(7662):222-6. https://doi.org/10.1038/nature23003

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21. https://doi.org/10.1038/nature22991

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234-9. https://doi.org/10.1038/s41586-018-0792-9

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. https://doi.org/10.1126/science.aaa4971

Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-Derived Neoantigens for Cancer Immunotherapy. Front Immunol. 2019;10:1856. https://doi.org/10.3389/fimmu.2019.01856

Aurisicchio L, Pallocca M, Ciliberto G, Palombo F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res. 2018;37(1):86. https://doi.org/10.1186/s13046-018-0751-1

Koşaloğlu-Yalçın Z, Lanka M, Frentzen A, Logandha Ramamoorthy Premlal A, Sidney J, Vaughan K, et al. Predicting T cell recognition of MHC class I restricted neoepitopes. Oncoimmunology. 2018;7(11):e1492508. https://doi.org/10.1080/2162402X.2018.1492508

Aldous AR, Dong JZ. Personalized neoantigen vaccines: a new approach to cancer immunotherapy. Bioorg Med Chem. 2018;26(10):2842-9. https://doi.org/10.1016/j.bmc.2017.10.021

Murillo R, Robles C. Research Needs for Implementing Cancer Prevention and Early Detection in Developing Countries: From Scientists' to Implementers' Perspectives. Biomed Res Int. 2019;2019:9607803. https://doi.org/10.1155/2019/9607803

World Health Organization. Global Report on Cancer. Geneva: WHO; 2020; in press.

Nature Editorial. A call for pragmatism in cancer research. Nat Rev Clin Oncol. 2018;15(4):193. https://doi.org/10.1038/nrclinonc.2018.41

Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019;19(6):349-58. https://doi.org/10.1038/s41568-019-0142-8

Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics. 2017;7(14):3585-94. https://doi.org/10.7150/thno.21471

International Agency for Research on Cancer/World Health Organization. Global Cancer Observatory [Internet]. Lyon: IARC; 2018. [Consultado el 15 de enero de 2020]. Disponible en: http://gco.iarc.fr

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382-99. https://doi.org/10.1158/2159-8290.CD-16-0577

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clin Cancer Res. 2019;25(19):5743-51. https://doi.org/10.1158/1078-0432.CCR-18-2641

Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018;15(3):183-92. https://doi.org/10.1038/nrclinonc.2017.186

Publicado
2020-11-30
Cómo citar
[1]
Murillo Moreno, R.H. 2020. Vacunas basadas en neoantígenos y control del cáncer: perspectivas. Revista Colombiana de Cancerología. 24, 4 (nov. 2020), 178-88. DOI:https://doi.org/10.35509/01239015.195.
Sección
Artículos especiales